Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

2013405 citationsJournal Article

Authors

Partnerships for the goals

Published in: The Lancet Oncology

Volume 14, Issue 13, pp. 1287-1294

Field-Weighted Citation Impact: 29.13